- Codis has completed the acquisition of Catalent’s Nottingham, UK facility, adding development-scale spray drying, oral solid dose formulation, analytical services, clinical supply, and small-scale commercial manufacturing capabilities.
- The acquisition complements Codis’ expanding commercial spray drying operations in Haverhill, with a new commercial spray dryer scheduled for validation in 2027.
Codis has completed the acquisition of Catalent’s Nottingham, UK facility, expanding its contract development and manufacturing organization (CDMO) capabilities in spray drying, amorphous solid dispersions (ASDs), and advanced particle engineering. The transaction combines development-scale spray drying, oral solid dose (OSD) formulation, analytical services, clinical supply, and small-scale commercial manufacturing in Nottingham with Codis’ commercial spray drying operations in Haverhill.
The acquisition complements Codis’ Haverhill facility, where a new GEA Pharma-SD® PSD-4 commercial spray dryer is scheduled for validation in 2027. According to the company, the combined facilities will provide customers with a pathway from early development through clinical supply and commercial intermediates to final oral dose forms, supporting contract manufacturing activities.
“This is an exciting milestone for Codis. We are delighted to welcome the Nottingham team into the Codis family. Their scientific strength, development experience, and long track record of delivering high-quality spray-dried and oral solid dose solutions make them an exceptional addition to our organization.”
Nicolas Fortin, CEO of Codis
Matthew Streeter, General Manager of the Nottingham site, has joined the Codis executive team following the acquisition. The company said the combined capabilities will expand its portfolio of bioavailability enhancement solutions while integrating development, analytical support, clinical supply, and commercial-scale spray drying services within a single organization.
Steve Facer, SVP Sales & Marketing at Codis, said the combined organization brings together development expertise, analytical support, clinical and small-scale commercial manufacturing, and commercial-scale spray drying under one quality system for customers developing poorly soluble molecules.
